São Paulo State University - UNESP, Botucatu, São Paulo, Brazil
Bauru Course of Medicine - USP, Botucatu, São Paulo, Brazil.
Perit Dial Int. 2019 Mar-Apr;39(2):183-187. doi: 10.3747/pdi.2018.00092.
Studies on vancomycin pharmacokinetics in acute kidney injury (AKI) patients on high-volume peritoneal dialysis (HVPD) are lacking. We studied the pharmacokinetics of intravenous (IV) vancomycin in AKI patients treated by HVPD who received a prescribed single IV dose of vancomycin (15 - 20 mg/kg total body weight) to determine the extent of vancomycin removal and to establish vancomycin dosing guidelines for the empirical treatment of AKI patients receiving HVPD. The application of 18 mg/kg vancomycin every 48 - 72 hours in AKI patients undergoing HVPD was required to maintain therapeutic concentrations.
关于接受高容量腹膜透析（HVPD）治疗的急性肾损伤（AKI）患者中万古霉素药代动力学的研究较少。我们研究了 HVPD 治疗的 AKI 患者单次静脉（IV）万古霉素（总体重 15-20mg/kg）的药代动力学，以确定万古霉素的清除程度，并为接受 HVPD 的 AKI 患者的经验性治疗建立万古霉素剂量指南。在接受 HVPD 的 AKI 患者中，每 48-72 小时应用 18mg/kg 的万古霉素可维持治疗浓度。
